Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hadley Phillips

Ophthalmology Elmwood Park, NJ Doctor of Osteopathy

NPI 1629036306 CMS profile 345354

619 River Dr, Elmwood Park, NJ 07407

Open in the dashboard

General payments

$10,640

183 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hadley Phillips of Elmwood Park, NJ is reported in the CMS Open Payments database as having received $10,640 across 183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $501 17
2024 General $561 15
2023 General $833 32
2022 General $969 45
2021 General $383 26
2020 General $6,390 14
2019 General $1,004 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hadley Phillips
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Hadley Phillips were reported at $501. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Hadley Phillips Ophthalmology median Middle half National median
2019 $1,004 $258 $104–$655 $163
2020 $6,390 $126 $45–$321 $114
2021 $383 $205 $76–$534 $132
2022 $969 $266 $100–$678 $149
2023 $833 $308 $117–$745 $160
2024 $561 $340 $127–$846 $164
2025 $501 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Carl Zeiss Meditec, Inc. $5,874 2 payments
  2. Alcon Vision LLC $1,630 24 payments
  3. Sun Pharmaceutical Industries Inc. $902 59 payments
  4. Johnson & Johnson Surgical Vision, Inc. $632 26 payments
  5. Glaukos Corporation $290 2 payments
  6. Ocular Therapeutix, Inc. $273 17 payments
  7. AbbVie, Inc. $244 16 payments
  8. Bausch & Lomb Americas Inc. $171 6 payments
  9. Harrow Eye, LLC $138 2 payments
  10. TissueTech, Inc. $126 6 payments
  11. Other $359 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $5,874 2 payments
  2. Food and Beverage $4,766 181 payments
Products named General payments · program years 2019–2025
  1. CLARUS $5,472 1 payment
  2. Cequa $726 46 payments
  3. Humphrey HFA $403 1 payment
  4. AcrySof IQ PanOptix $387 4 payments
  5. ReSTOR $329 6 payments
  6. DEXTENZA $273 17 payments
  7. Clareon $258 4 payments
  8. AcrySof IQ VIVITY $208 2 payments
  9. BromSite $188 14 payments
  10. iDose $166 1 payment
  11. Other $2,379 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

488

Median for Ophthalmology: 891

Drug cost

$70,085

Median for Ophthalmology: $68,233

Branded share of claims

13.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 35 $36,855
Prednisolone Acetate Generic 380 $17,692
Xiidra Lifitegrast Brand 12 $13,988
Ketorolac Tromethamine Generic 26 $1,045
Latanoprost Generic 15 $271
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 20 $234

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$219,992

Medicare's payments for the services billed

Medicare patients

337

Average age 75

Services billed

1,116

213 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 37%
Ischemic heart disease 33%
Osteoporosis 17%
Chronic kidney disease 16%
COPD 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cequa
  • Sun Pharmaceutical Industries Inc. $78
$78 — —
DEXTENZA
  • Ocular Therapeutix, Inc. $31
$31 — —
OXERVATE
  • Dompe US, Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record